eFFECTOR Therapeutics Inc

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

During the post-SPAC spectacle, EFTR stock be volatile - this should be expected. Still, eFFECTOR's oncology therapies look promising.

eFFECTOR Therapeutics Stock Might Be Worth the Risk in Small Quantities

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference at 2:40 p.m. ET on Tuesday, September 28, 2021. eFFECTOR will also host investor meetings throughout the conference.

eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference

eFFECTOR Therapeutics Inc (NASDAQ: EFTR) is trading higher Monday after Cantor Fitzgerald initiated coverage on the stock. Cantor Fitzgerald analyst Louise Chen initiated coverage on eFFECTOR Therapeutics with an Overweight rating and announced a price target of $50.

What's Going On With eFFECTOR Therapeutics Stock Today?

eFFECTOR Therapeutics is pioneering the development of a new class of oncology drugs known as STRIs. The STRI therapy is also being evaluated for COVID-19 at UCSF under a DARPA grant.

eFFECTOR: Developing New Class Of Cancer Therapies

The biotech's novel cancer platform is fueling buyout speculation on social media today.

Why eFFECTOR Therapeutics Stock Is Heating Up Today

Here's what investors may want to know about eFFECTOR and EFTR stock, as the company's shares surge once again today in a big way. The post EFTR Stock: 7 Things to Know About eFFECTOR as Shares Shoot Up 100% appeared first on InvestorPlace.

EFTR Stock: 7 Things to Know About eFFECTOR as Shares Shoot Up 100%

After a tough week for SPACs, EFTR stock has enjoyed significant gains today. The SPAC bubble may not be over yet.

EFTR Stock: What Is Going on With Red-Hot eFFECTOR Therapeutics Today?

Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRW Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRW

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

News for eFFECTOR Therapeutics Inc Stock (EFTR)